Corvus Pharmaceuticals (CRVS) P/E Ratio
P/E Ratio as of Jun 13, 2025: -4.26
Average-3.94
Median-3.85
Minimum-4.57
Maximum-3.53
-4.26
Past Month-0.62 (17.03%)
The P/E ratio for Corvus Pharmaceuticals (CRVS) is -4.26 as of Jun 13, 2025. This represents a decrease of -41.40% compared to its 12-month average P/E ratio of -7.27. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Corvus Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Corvus Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Corvus Pharmaceuticals to industry peers.
Corvus Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Corvus Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Corvus Pharmaceuticals to industry peers.
Corvus Pharmaceuticals (CRVS) P/E Ratio Insights
See Corvus Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Corvus Pharmaceuticals (CRVS)
Order type
Buy in
Order amount
Est. shares
0 shares
Corvus Pharmaceuticals (CRVS) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 2, 2025 | $4.03 | -4.10 |
| May 1, 2025 | $3.52 | -3.64 |
| Apr 1, 2025 | $3.17 | -3.28 |
| Mar 3, 2025 | $3.95 | -4.26 |
| Feb 3, 2025 | $5.07 | -5.47 |
| Jan 2, 2025 | $5.43 | -5.86 |
Corvus Pharmaceuticals (CRVS) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -4.26 | -26.30% |
| 2024 | -5.78 | +110.18% |
| 2023 | -2.75 | +183.51% |
| 2022 | -0.97 | -57.46% |
| 2021 | -2.28 | -86.69% |
| 2020 | -17.13 | — |
FAQs About Corvus Pharmaceuticals (CRVS) P/E ratio
The latest P/E ratio of Corvus Pharmaceuticals (CRVS) is -4.26, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Corvus Pharmaceuticals’s last 12-month average P/E ratio is -7.27, compared to its current P/E ratio of -4.26. This reflects a decrease of -41.40%.
Corvus Pharmaceuticals’s current P/E ratio of -4.26 is lower than its last 12-month average P/E of -7.27. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Corvus Pharmaceuticals’s average P/E ratio over the last 3 years is -3.86. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Corvus Pharmaceuticals’s average P/E ratio over the last 5 years is -7.49. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.